Drugs / ABT-072
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00982826 | Sep → Dec 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00890318 | Apr → Jul 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00752687 | Sep 2008 → May 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01221298 | Oct 2010 → May 2011 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01074008 | Mar 2010 → Jun 2011 | chronic hepatitis C virus infection | AbbVie | Completed | Mixed |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01081483 Comparator | Mar → Jun 2010 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00947440 Comparator | Jul → Aug 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00872196 Background | Apr 2009 → Apr 2010 | hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2012-04-19 | Enanta Pharmaceuticals, Inc | Results Abbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C enanta.com ↗ |
| 2012-04-04 | Enanta Pharmaceuticals, Inc | Results Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL enanta.com ↗
In a separate study, known as "Pilot", 91 percent of genotype 1 infected, treatment-naïve patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-04-19 | Enanta Pharmaceuticals, Inc | Abbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C enanta.com ↗ |
| 2012-04-04 | Enanta Pharmaceuticals, Inc | Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL enanta.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-072 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00890318 ↗ |
| Action | Inhibit | “ABT-072 is a non-nucleoside NS5B polymerase inhibitor” PMID 23439262 ↗ Feb 2013 |
| Modality | Small molecule | — CHEMBL4076467 ↗ |
| Route | Oral | “blinded, single ascending oral doses of ABT 072” NCT01081483 ↗ |